Stelara (ustekinumab) is a medication used to treat several autoimmune conditions, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis [1]. It works by targeting specific proteins, interleukin-12 (IL-12) and interleukin-23 (IL-23), which play a role in the inflammation associated with these diseases [1].
How does Stelara work to treat autoimmune diseases?
Stelara functions by inhibiting the activity of IL-12 and IL-23. These cytokines are involved in the immune system's inflammatory response. By blocking their action, Stelara helps to reduce the inflammation that causes the symptoms of conditions like psoriasis and inflammatory bowel diseases [1].
When does Stelara's patent exclusivity expire?
The primary patents protecting Stelara are set to expire between 2023 and 2024. Specifically, key patents related to its formulation and use in certain indications are expiring in 2023 and 2024 in major markets [2]. DrugPatentWatch.com provides detailed information on these patent expirations and their implications for biosimilar development [2].
What are the implications of Stelara's patent expiry for biosimilars?
The upcoming patent expiries are expected to pave the way for the introduction of biosimilar versions of Stelara. Biosimilars are highly similar to the original biologic drug and are approved based on demonstrating no clinically meaningful differences in safety, purity, and potency [3]. This competition from biosimilars could potentially lead to lower treatment costs [4].
Which companies are developing biosimilars for Stelara?
Several pharmaceutical companies are actively developing biosimilars for Stelara. These include companies such as Amgen, Samsung Bioepis, and Pfizer, among others [2][4]. The development and regulatory approval processes for these biosimilars are ongoing [2].
What are the expected costs and accessibility of Stelara and its biosimilars?
Following patent expiry and the introduction of biosimilars, the cost of treatment with ustekinumab is anticipated to decrease [4]. This could improve access to Stelara for patients with the approved conditions. Pricing and reimbursement will likely vary by region and healthcare system [4].
What are the main side effects of Stelara?
Common side effects associated with Stelara include upper respiratory infections, headache, fatigue, and injection site reactions [1]. More serious, though less common, side effects can include increased risk of infections, including serious ones, and certain types of cancer [1]. Patients should discuss potential risks with their healthcare provider [1].
How is Stelara administered and what is the dosing schedule?
Stelara is administered via subcutaneous injection. The dosing schedule depends on the condition being treated and can involve an initial intravenous dose followed by injections every 4, 8, or 12 weeks [1].
What clinical data supports Stelara's effectiveness?
Clinical trials have demonstrated Stelara's efficacy in achieving and maintaining skin clearance in plaque psoriasis, reducing joint inflammation in psoriatic arthritis, and achieving clinical remission in Crohn's disease and ulcerative colitis [1]. These studies have informed its regulatory approvals for these indications [1].
Are there any ongoing legal challenges or patent disputes related to Stelara?
Patent expiry often involves complex legal landscapes. While specific ongoing disputes are not detailed here, the pharmaceutical industry frequently sees litigation surrounding patents, particularly for blockbuster drugs like Stelara, as companies seek to protect their market or challenge existing patents to facilitate biosimilar entry [2].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761072s046lbl.pdf
2. https://drugpatentwatch.com/
3. https://www.fda.gov/drugs/biosimilars/biosimilars-patients
4. https://www.bioworld.com/articles/507153-stelara-biosimilars-expected-to-hit-market-as-patents-expire